AstraZeneca reports positive results from the ADRIATIC phase III trial of Imfinzi in patients with limited-stage small-cell lung cancer

The ADRIATIC phase III trial unveiled promising results indicating AstraZeneca’s Imfinzi (durvalumab) significantly enhanced overall survival (OS) and progression-free survival (PFS) in limited-stage small cell lung cancer (LS-SCLC) patients post-concurrent chemoradiotherapy (cCRT) compared to placebo.

LS-SCLC, an aggressive form of lung cancer, often relapses rapidly despite initial chemotherapy and radiotherapy response, with a bleak prognosis. Imfinzi's safety profile aligned with expectations, with no new safety signals detected.

These findings will be presented at forthcoming medical meetings and shared with regulatory authorities worldwide.

The trial's second arm, assessing Imjudo (tremelimumab) in addition to Imfinzi, remains blinded for further analysis.

The ADRIATIC trial, a global randomized, double-blind, placebo-controlled phase III trial, evaluated Imfinzi monotherapy and Imfinzi plus Imjudo versus placebo in 730 LS-SCLC patients post-cCRT. The trial encompassed 164 centers across 19 countries.

Imfinzi (durvalumab) is a human monoclonal antibody targeting PD-L1, disrupting tumour immune evasion mechanisms and reinstating immune response inhibition.